Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
Guardado en:
Autores principales: | Yuliya Lytvyn, PhD, Asfandyar Mufti, MD, Hiba Zaaroura, MD, Muskaan Sachdeva, BHSc, Justin D. Lu, MSc, Brian D. Rankin, PhD, Vimal H. Prajapati, MD, Ronald Vender, MD, Jensen Yeung, MD, FRCPC |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e5569883aea8428a970c97f32babd322 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado Á, et al.
Publicado: (2018) -
Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
por: Reddy V, et al.
Publicado: (2020) -
Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis
por: Annunziata Dattola, et al.
Publicado: (2021) -
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: Riccardo G. Borroni, et al.
Publicado: (2021) -
MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Katsuhiro Yoshimura, MD, PhD, et al.
Publicado: (2021)